Ajing Xu

Dr. Ajing Xu

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Phytomedicine
Verified
Journal Article
Open access
XLXiandeng Li
Xiandeng Li
SZShuyan Zhao
Shuyan Zhao
JXJing Xie
Jing Xie
MLMi Li
Mi Li
STShuangmei Tong
Shuangmei Tong
AXAjing Xu
Ajing Xu
Although recent progress provides mechanistic insights into diabetic nephropathy (DN), effective treatments remain scarce. DN, characterized by proteinuria and a progressive decline in renal function, primarily arises from podocyte injury, which impairs the glomerular filtration barrier. Wogonoside, a bioactive compound from the traditional Chinese herb Scutellaria baicalensis, has not been explored for its role in DN. This study aimed to investigate the therapeutic effects of wogonoside on podocyte injury in DN and its molecular mechanisms. The effects of wogonoside were examined using HFD/STZ-induced DN mouse models and high glucose (HG)-induced MPC-5 cells. Oxidative stress and inflammation markers were analyzed via Western blot and RT-qPCR. Wogonoside targets were identified through DARTS-MS and validated by SPR, molecular docking, alanine scanning, and CETSA. RNA-Seq analysis was employed to identify downstream targets, and the p65-MMP28 axis was explored through p65 knockdown and overexpression studies. The regulatory effect of p65 on Mmp28 was confirmed through dual-luciferase reporter assays and ChIP-qPCR. Wogonoside treatment significantly reduced oxidative stress and inflammation in vivo and in vitro. Mechanistic studies identified p65 as a direct target of wogonoside, with SPR confirming a strong binding affinity (KD = 25.05 μM). Molecular docking and alanine scanning identified LYS221 as a critical binding site, which was further supported by CETSA using the p65 K221A mutant. RNA-Seq analysis revealed Mmp28 as a downstream effector of p65 involved in HG-induced podocyte injury. Functional studies demonstrated that wogonoside's protective effects on antioxidant and inflammatory pathways are mediated via the p65-MMP28 axis. Dual-luciferase reporter assays revealed that p65 regulates Mmp28 transcription, and ChIP-qPCR confirmed its direct promoter binding. This study highlights wogonoside as a promising candidate for the treatment of podocyte injury in DN by targeting the NF-κB p65-MMP28 signaling axis. These findings provide novel insights into wogonoside's therapeutic potential and its molecular mechanisms, paving the way for its further development as a DN intervention.

9 April 2026 in Medcomm
Verified
Journal Article
Open access
QWQiu Wang
Qiu Wang
ZBZunjie Bo
Zunjie Bo
YZYa Zhang
Ya Zhang
YCYun Chen
Yun Chen
ZWZhiyu Wang
Zhiyu Wang
YLYan Liu
Yan Liu
The histone‐lysine N‐methyltransferase (KMT2) family is a central epigenetic regulator whose dysfunction drives diverse human diseases through distinct molecular mechanisms. In acute leukemias, KMT2A rearrangements aberrantly recruit transcriptional cofactors, activating oncogenic gene programs; in solid tumors, loss‐of‐function mutations in KMT2C/D disrupt enhancer‐mediated regulatory networks, compromising cellular identity and genome stability; in neurodevelopmental disorders, germline haploinsufficiency of KMT2A/B/D impairs developmental epigenetic programming. Despite increasingly comprehensive understanding of the pathogenic mechanisms involving KMT2 family members, a unified framework translating these molecular insights into effective, subtype‐specific therapeutic strategies has been lacking. This review comprehensively deconstructs these pathogenic pathways and explores how mechanistic insights are being translated into novel therapeutic strategies, including direct targeting of oncogenic transcriptional complexes, exploiting vulnerabilities from tumor suppressor loss, and modulating the tumor immune microenvironment. We systematically synthesize recent clinical advances, from small‐molecule inhibitors against protein–protein interactions (e.g., menin–KMT2A), to targeted degraders (PROTACs), epigenetic readers/writers inhibitors (e.g., BET, LSD1, DOT1L), and rational combination regimens with chemotherapy or immunotherapy. By integrating the biological characteristics of KMT2 with translational medicine and clinical evidence, this study provides a framework for advancing precision medicine approaches based on the molecular subtypes driven by KMT2.

1 June 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JXJing Xie
Jing Xie
GSGuojun Shi
Guojun Shi
MWMo Wang
Mo Wang
YZYuwen Zhong
Yuwen Zhong
YYYue Yuan
Yue Yuan
AXAjing Xu
Ajing Xu
Aim: The p38 MAPK pathway governs the core innate immune response in Caenorhabditis elegans ( C. elegans ), yet the negative regulatory networks preventing immune overactivation—and their potential as therapeutic targets—remain elusive. We aimed to identify novel phosphatase checkpoints in host defense, elucidate their molecular mechanisms, and validate their druggability using small-molecule interventions. Methods: We performed a genome-wide RNAi screen of 166 phosphatase genes in C. elegans infected with Pseudomonas aeruginosa (PA14) to identify key regulators. The molecular mechanism was dissected using yeast two-hybrid screening, Co-IP, and mutagenesis assays. Furthermore, a small-molecule screen was performed to identify compounds capable of interfering with PTP-4 function, followed by Surface Plasmon Resonance (SPR), molecular docking, and structural biology approaches to characterize compound–PTP-4 interactions. Results: PTP-4 was identified as a critical negative regulator of immunity. Genetic deficiency of ptp-4 significantly enhanced host resistance via hyperactivation of the p38 MAPK (PMK-1) pathway. Mechanistically, PTP-4 physically interacts with ATLN-1, an ER-shaping GTPase, through its phosphatase domain, thereby suppressing immune activation. Crucially, baicalin was identified through compound screening as an inhibitor of P. aeruginosa infection. Structural and biochemical analyses revealed a dual mechanism of action: baicalin directly binds to the PTP-4/ATLN-1 interface with high affinity (K D = 28.69 μM) to allosterically disrupt their complex formation, while concurrently downregulating PTP-4 protein expression. This “dual-hit” inhibition mimics the genetic loss of ptp-4 , effectively unleashing the innate immune response. Conclusion: Our study uncovers the PTP-4/ATLN-1 axis in the control of P. aeruginosa infection. Importantly, we provide the first proof-of-concept that this axis is a druggable target. By demonstrating that baicalin boosts host immunity through the specific dismantling of the PTP-4/ATLN-1 complex, we highlight a novel therapeutic strategy for combating bacterial infections.

12 July 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
YYYue Yuan
Yue Yuan
JXJing Xie
Jing Xie
MWMo Wang
Mo Wang
YLYishan Li
Yishan Li
XZXinxin Zhang
Xinxin Zhang
AXAjing Xu
Ajing Xu
Metabolic disorders encompass a spectrum of pathologies driven by the dysregulation of systemic metabolic homeostasis. Their escalating global prevalence has positioned these conditions at the forefront of contemporary biomedical research. Protein tyrosine phosphatase non-receptor type 2 (PTPN2) regulates cellular tyrosine phosphorylation and links metabolic perturbations to altered signal transduction. Functionally, PTPN2 modulates immune responses, cellular proliferation, and metabolic signaling pathways. Consequently, it influences immunological tolerance, glucose and lipid metabolism, and insulin sensitivity in a context-dependent manner. To facilitate the identification of novel therapeutic targets, this review systematically delineates the molecular mechanisms underlying PTPN2 function across diverse metabolic pathologies. Specifically, we examine its involvement in type 1 diabetes, type 2 diabetes, diabetic complications, and metabolic dysfunction-associated steatohepatitis. Furthermore, we highlight recent advances in PTPN2-targeted interventions, with a particular emphasis on type 2 diabetes research, while critically evaluating existing clinical challenges and future translational prospects. Ultimately, this synthesis provides an integrated perspective for the development of precision medicine strategies in the management of metabolic diseases.